IntroducingImportant SafetyInformationPrescribing Information /Medication GuideAlogliptinNesina® Authorized GenericPrescribing InformationMedication GuideAlogliptin and Metformin HClKazano® Authorized GenericPrescribing InformationMedication GuideAlogliptin and PioglitazoneOseni® Authorized GenericPrescribing InformationMedication GuideTo help manage type 2 diabetes in multiple patients.For appropriate patients with type 2 diabetes in addition to diet and exercise.Indication: Alogliptin, Alogliptin and Metformin HCl, and Alogliptin and Pioglitazone are indicated as an adjunct to diet and exerciseto improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin, Alogliptin and Metformin HCl, and Alogliptin andPioglitazone are not for treatment of type 1 diabetes or diabetic ketoacidosis.Important Safety Information for Alogliptin, Alogliptin and Metformin HCl, and Alogliptin and PioglitazoneWARNING: CONGESTIVE HEART FAILURE—for Alogliptin and PioglitazoneThiazolidinediones, including pioglitazone, which is a component of Alogliptin and Pioglitazone, cause or exacerbate congestive heart failure in some patients.After initiation of Alogliptin and Pioglitazone, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone in Alogliptin and Pioglitazone must be considered.Alogliptin and Pioglitazone is not recommended in patients with symptomatic heart failure.Initiation of Alogliptin and Pioglitazone in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated.WARNING: LACTIC ACIDOSIS—for Alogliptin and Metformin HClLactic acidosis is a rare, but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure.The onset is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap, and elevated blood lactate.If acidosis is suspected, Alogliptin and Metformin HCl should be discontinued and the patient hospitalized immediately.Alogliptin, Alogliptin and Metformin HCl, and Alogliptin and Pioglitazone are contraindicated in patients with ahistory of serious hypersensitivity reaction to any of the components of these products, such as anaphylaxis,angioedema, or severe cutaneous adverse reactions.Alogliptin and Metformin HCl is contraindicated in patients with renal impairment (e.g., serum creatinine levels 1.5mg/dL for men, 1.4 mg/dL for women or abnormal creatinine clearance), which may also result from conditionssuch as cardiovascular co